Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

Cancer Immunology, Immunotherapy

Volumn 54, Issue 10, 2005, Pages 1018-1025

  Livingston, P O ^a   Hood, C ^a   Krug, L M ^a   Warren, N ^a   Kris, M G ^a   Brezicka, T ^a   Ragupathi, G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibodies; Antigens; Gangliosides; Immunotherapy; SCLC; Tumor vaccine

Indexed keywords

ANTIBODY; CANCER VACCINE; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; GANGLIOSIDE GM1; GANGLIOSIDE GM2; MONOCLONAL ANTIBODY; POLYSIALIC ACID;

ANTIBODY PRODUCTION; ARTICLE; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFLAMMATION; LUNG SMALL CELL CANCER; OPSONIZATION; PRIORITY JOURNAL; SCREENING;

ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOMA, SMALL CELL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; G(M1) GANGLIOSIDE; G(M2) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; SIALIC ACIDS; TUMOR CELLS, CULTURED;

EID: 23944472365     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0663-8     Document Type: Article

References (32)

1. Brezicka FT, Olling S, Nilsson O, Bergh J, Holmgren J, Sorenson S, Yngvason F, Lindholm L (1989) Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res 49(5):1300-1305
2. Brezicka T, Bergman B, Olling S, Fredman P (2000) Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer 28(1):29-36
3. Caragine TA, Okada N, Frey AB, Tomlinson SA (2002) Tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res 62(4):1110-1115
4. Chapman PB, Livingston P, Morrison ME, Williams L, Houghton AN (1994) Immunization of melanoma patients with antiidiotype monoclonal antibody bec2 (which mimics GD3 ganglioside): pilot trials using no immunological adjuvant. Vaccine Res 3(2):59-69
5. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46(10):5112-5118
6. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME (1988) Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81(4):1122-1128
7. Colten HR, Rosen FS (1992) Complement deficiencies. Annu Rev Immunol 10:809-834
8. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC (1999) Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5(10):2773-2779
9. Giaccone G, Debruyne C, Felip E, Millward M, D'Addario G, Thiberville L, Rome L, Zatloukal P, Legrand C (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol (Meeting Abstracts) 22(14_suppl):7020
10. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55(13):2783-2788
11. Huntsberger DV, Leaverton P (1970) Statistical inference in the biomedical sciences. Allyn and Bacon Inc., Boston
12. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71(6):1049-1055
13. Joiner KA (1988) Complement evasion by bacteria and parasites. Annu Rev Microbiol 42:201-230
14. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU (1991) Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 139(2):297-304
15. Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO (2004) Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10(3):916-923
16. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccinatin of patients with small cell lung cancer with synthetic fucosyl GM1 conjugated to Keyhole Limpet Hemocyanin (KLH). Clin Cancer Res 10:6094-6102
17. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO (2005) Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 174:5706-5712
18. Livingston P, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M (1997) Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 43(6):324-330
19. Moffitt MC, Frank MM (1994) Complement resistance in microbes. Springer Semin Immunopathol 15(4):327-344
20. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129(1):184-189
21. Nilsson O, Mansson JE, Brezicka T (1984) Fucosyl-GM1-A ganglioside associated with small cell lung carcinomas. Glycoconjugate 1:43-49
22. Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO (2002) Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20(7-8):1030-1038
23. Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO (2003) A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother 52(10):608-616
24. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ (2003) Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9(14):5214-5220
25. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85(5):659-666
26. Ragupathi G, Slovin S, Adluri S, Sames D, Kim IJ, Kim HM, Spassova M, Bornmann W, Lloyd KO, Scher HI, Livingston PO, Danishefsky SJ (1999) A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew Chem Int Ed 38(4):563-566
27. Sakuma T, Kodama K, Hara T, Eshita Y, Shibata N, Matsumoto M, Seya T, Mori Y (1993) Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jpn J Cancer Res 84(7):753-759
28. Scheidegger EP, Lackie PM, Papay J, Roth J (1994) In vitro and in vivo growth of clonal sublines of human small cell lung carcinoma is modulated by polysialic acid of the neural cell adhesion molecule. Lab Invest 70(1):95-106
29. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI (1999) Carbohydrate vaccines in cancer: immimogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci 96:5710-5715
30. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73(1):42-49
31. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 4(11):2669-2676
32. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73(1):50-56